CL2007000912A1 - Metodo para el tratamiento de la hipertension que comprende administrar un inhibidor de renina o una sal farmaceuticamente aceptable del mismo, mediante lo cual se sostiene un efecto antihipertensivo mas alla del cese de la administracion de renina. - Google Patents

Metodo para el tratamiento de la hipertension que comprende administrar un inhibidor de renina o una sal farmaceuticamente aceptable del mismo, mediante lo cual se sostiene un efecto antihipertensivo mas alla del cese de la administracion de renina.

Info

Publication number
CL2007000912A1
CL2007000912A1 CL200700912A CL2007000912A CL2007000912A1 CL 2007000912 A1 CL2007000912 A1 CL 2007000912A1 CL 200700912 A CL200700912 A CL 200700912A CL 2007000912 A CL2007000912 A CL 2007000912A CL 2007000912 A1 CL2007000912 A1 CL 2007000912A1
Authority
CL
Chile
Prior art keywords
rhenine
antihipertensive
administrating
renin
hypertension
Prior art date
Application number
CL200700912A
Other languages
English (en)
Inventor
Andrew Satlin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38420678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007000912(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2007000912A1 publication Critical patent/CL2007000912A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL200700912A 2006-04-03 2007-04-02 Metodo para el tratamiento de la hipertension que comprende administrar un inhibidor de renina o una sal farmaceuticamente aceptable del mismo, mediante lo cual se sostiene un efecto antihipertensivo mas alla del cese de la administracion de renina. CL2007000912A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78884206P 2006-04-03 2006-04-03

Publications (1)

Publication Number Publication Date
CL2007000912A1 true CL2007000912A1 (es) 2008-03-14

Family

ID=38420678

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200700912A CL2007000912A1 (es) 2006-04-03 2007-04-02 Metodo para el tratamiento de la hipertension que comprende administrar un inhibidor de renina o una sal farmaceuticamente aceptable del mismo, mediante lo cual se sostiene un efecto antihipertensivo mas alla del cese de la administracion de renina.

Country Status (20)

Country Link
US (1) US20090062395A1 (es)
EP (1) EP2004167A1 (es)
JP (1) JP2009532494A (es)
KR (1) KR20080108515A (es)
CN (1) CN101415413A (es)
AU (1) AU2007234917B2 (es)
BR (1) BRPI0710095A2 (es)
CA (1) CA2645260A1 (es)
CL (1) CL2007000912A1 (es)
IL (1) IL193905A0 (es)
MA (1) MA30387B1 (es)
MX (1) MX2008012729A (es)
NO (1) NO20084625L (es)
NZ (1) NZ571251A (es)
RU (1) RU2008143055A (es)
SG (1) SG170830A1 (es)
TN (1) TNSN08383A1 (es)
TW (1) TW200806283A (es)
WO (1) WO2007118023A1 (es)
ZA (1) ZA200807615B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087116A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Use of spp100 for the treatment of acute mi
CN102212012A (zh) * 2010-04-12 2011-10-12 上海源力生物技术有限公司 一种合成阿利克伦的中间体及其制备方法
EP2768971A1 (en) 2011-10-20 2014-08-27 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for the detection and the treatment of cardiac remodeling
EP3956021A4 (en) * 2019-04-18 2023-06-14 EyePoint Pharmaceuticals, Inc. METHOD OF TREATMENT OF HIGH BLOOD PRESSURE WITH ACTIVATORS OF TIE-2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5659065A (en) * 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
US5606078A (en) * 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US20060013852A1 (en) * 2002-06-28 2006-01-19 Prescott Margaret F Use of organic compounds
WO2004100871A2 (en) * 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
WO2005037317A2 (en) * 2003-10-17 2005-04-28 Cornell Research Foundation, Inc. Mast cell-derived renin
AR048431A1 (es) * 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
DE602004015343D1 (de) * 2004-09-27 2008-09-04 Pantarhei Bioscience Bv Behandlung oder prävention von unplanmässigen blutungen bei frauen unter progestogenhaltiger medikation

Also Published As

Publication number Publication date
IL193905A0 (en) 2009-08-03
MX2008012729A (es) 2008-10-14
NO20084625L (no) 2008-11-03
RU2008143055A (ru) 2010-05-10
BRPI0710095A2 (pt) 2011-08-02
AU2007234917B2 (en) 2011-05-12
CA2645260A1 (en) 2007-10-18
US20090062395A1 (en) 2009-03-05
AU2007234917A1 (en) 2007-10-18
WO2007118023A1 (en) 2007-10-18
NZ571251A (en) 2011-12-22
TNSN08383A1 (en) 2009-12-29
MA30387B1 (fr) 2009-05-04
SG170830A1 (en) 2011-05-30
ZA200807615B (en) 2009-10-28
JP2009532494A (ja) 2009-09-10
EP2004167A1 (en) 2008-12-24
TW200806283A (en) 2008-02-01
KR20080108515A (ko) 2008-12-15
CN101415413A (zh) 2009-04-22

Similar Documents

Publication Publication Date Title
PA8850801A1 (es) Compuestos útiles para inhibir chk1
CL2009000915A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-bencenosulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica (copd).
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
ECSP088786A (es) Tratamientos de las alergias oculares
CL2009000914A1 (es) Compuestos derivados de 1-ciano-3-pirrolidinil-n-sustituidas-sulfonamidas, inhibidores de catepsina c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una enfermedad pulmonar obstructiva cronica.
CL2010001361A1 (es) Compuestos derivados de piperidin-carboxamida, inhibidores de renina; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de una enfermedad circulatoria, hipertension y/o diversos daños organicos atribuibles a la hipertension.
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
PA8852901A1 (es) Inhibidores de proteina cinasa
GT200900283A (es) &#34;terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario&#34;.
RS52874B (en) THYOPHEN ANALYSIS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
MA32934B1 (fr) Combinaisons inhibitrices hsp90
UY30056A1 (es) Administracion transdermica de meptazinol
DOP2006000170A (es) Nuevos derivados de espirocromanona
ECSP14013179A (es) Compuesto inhibidor de la señalización de la trayectoria notch
GT200600160A (es) Tratamiento del dolor
GT201200038A (es) Composicion para tratar la fibrosis quistica
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
DOP2008000053A (es) Inhibidores de akt(proteinas cinasa b)
GT200900065A (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk
AR062390A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas
CL2007003467A1 (es) Metodo para el tratamiento de una enfermedad proliferativa seleccionada a partir de sindrome mielodisplasico o leucemia mieloblastica aguda que comprende administrar a) un inhibidor de desacetilasa de histona (hdac) de formula definida en combinacion
SV2016005313A (es) Derivados de carboxamida
CL2011002233A1 (es) Metodo para tratar o prevenir el cancer, que comprende administrar una combinacion farmaceutica sinergica de: a) (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonamida y b) 3-(6,7-bis(2-metoxietoxi)quinazolin-4-ilamino)benzonitrilo; composicion farmaceutica; y kit farmaceutico.
GT201300263A (es) Combinación de un inhibidor de cinasa de fosfatidilinositol-3 (pi3k) y un inhibidor de mtor
ECSP088781A (es) Derivados de benzimidazol